Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and outcomes with VOD treatment following hematopoietic cell transplantation in adult and pediatric patients. Biology of Blood and Marrow Transplantation

There is no transfer of value with the eAccess view of this publication and, therefore, no Sunshine Act reporting.

Disclaimer

This journal article reprint is being provided as a professional courtesy by Jazz Pharmaceuticals, Inc. This scientific publication contains information that may or may not be contained within the accompanying package insert. Providing this reprint should not be construed as a recommendation for use of any Jazz Pharmaceuticals product for nonapproved uses. Prior to prescribing, please refer to the accompanying Prescribing Information, which includes the approved indication and a discussion of the benefits and risks associated with our product.

The opinions expressed in this reprint do not necessarily reflect those of Jazz Pharmaceuticals. Readers are encouraged to contact the primary authors with questions regarding the content of the reprint. Jazz Pharmaceuticals does not assume responsibility for any injury and/or damage to persons or property out of or related to any use of the information contained in this reprint.

Financial Disclosure Statement

This study was supported by Jazz Pharmaceuticals. Conflict of interest statement: S.C. has served as a consultant to and received honoraria from Gentium/Jazz Pharmaceuticals. N.A.K. received grants from Gentium during the course of the study. N.A.K.'s research was supported by the National Cancer Institute of the National Institutes of Health under award P30 CA008748; the content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health. A.P. has served on advisory boards and the speakers bureau for and received honoraria from Jazz Pharmaceuticals. R.J.R. and W.T. are employees of and hold stock and/or stock options in Jazz Pharmaceuticals. P.G.R. has served on advisory committees and received honoraria from Jazz Pharmaceuticals.

Detailed information on funding amounts received by the authors of this publication is available at http://www.cms.gov/openpayments.

INDICATION

Defitelio^® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).